Novartis’ Cosentyx fails Phase 3 study for autoimmune diseasenews2025-07-03T15:07:04+00:00July 3rd, 2025|Endpoints News|
Structure in partnering talks for oral GLP-1 as mid-stage readout nearsnews2025-07-03T12:00:15+00:00July 3rd, 2025|Endpoints News|
4DMT lays off staff, reshuffles team as it doubles down on Phase 3 plansnews2025-07-03T11:13:01+00:00July 3rd, 2025|Endpoints News|
Bristol Myers’ China partner touts Phase 3 success for EGFRxHER3 bispecific ADCnews2025-07-02T17:57:11+00:00July 2nd, 2025|Endpoints News|
Vyne stops enrolling early-stage psoriasis study following clinical hold lift, early datanews2025-07-02T15:32:39+00:00July 2nd, 2025|Endpoints News|
AbbVie cans oral ulcerative colitis drug from Landos buyoutnews2025-07-02T15:28:28+00:00July 2nd, 2025|Endpoints News|
Shionogi, BioVersys team up on ansamycin antibiotics in deal worth up to $614Mnews2025-07-02T05:00:50+00:00July 2nd, 2025|Endpoints News|
PBM reforms fail to make Senate version of Trump’s megabillnews2025-07-01T20:00:46+00:00July 1st, 2025|Endpoints News|
Advocates urge J&J to ‘put everything on the table’ for gene therapy despite failed trialnews2025-07-01T14:48:52+00:00July 1st, 2025|Endpoints News|
Beckley touts positive mid-stage psychedelic data, advancing atai mergernews2025-07-01T10:00:50+00:00July 1st, 2025|Endpoints News|
